Ho M, et al. - Researchers designed this study to determine the proportion of patients with metastatic pancreatic cancer (MPC) who would be eligible for FOLFIRINOX based upon the pivotal ACCORD study criteria. Findings revealed the proven survival benefit of FOLFIRINOX. However, in the real-world setting, only approximately one-quarter of patients with MPC would have been considered eligible for such therapy based upon the ACCORD eligibility criteria. They highlight the necessity for careful patient selection and more tolerable therapies.

Methods

• From the Gastrointestinal Cancers Outcomes Unit Database (GICOU), researchers identified patients with confirmed MPC at the time of referral to the BC Cancer Agency between 2004 and 2007.
• They used chart review to determine the proportion of patients that met the ACCORD study eligibility criteria.
• They used descriptive statistics to assess criteria for FOLFIRINOX exclusion.

Results

• Researchers identified a total of 100 consecutive patients with complete chart records and MPC.
• Among them, 52 (52%) were male and the median age was 68 years (range, 42 to 98 y).
• In this study, liver (63%) and peritoneum (22%) were identified as the most common sites of metastases.
• The ACCORD study eligibility criteria was fulfilled by only 26 patients.
• In this study, the most common reasons for FOLIFIRINOX exclusion per ACCORD were poor Eastern Cooperative Oncology Group score of ≥2 (64%), age of 76 years or greater (22%), elevated bilirubin (22%), and inadequate renal function (6%).